Immunotherapies such as CAR-T are extending survival, yet reliance on inpatient monitoring for cytokine release syndrome continues to restrict access. This article explores how continuous digital monitoring and AI-driven analysis could enable safer outpatient delivery and support more scalable immunotherapy adoption.

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.

Ohio University researchers have discovered that blocking the growth hormone receptor could make lung cancer treatments more effective, offering potential new treatments for patients with therapy-resistant tumours.

Scientists at Arizona State University have discovered that the way nanoparticles interact with water determines how they behave inside the human body, providing a new thermodynamic framework that could lead to more effective nanomedicines.

Japanese researchers have identified a molecular pathway linking chronic liver congestion to fibrosis and tumour formation, offering a potential new target for therapies to prevent serious liver disease.

A newly identified protein essential to the survival of trypanosome parasites could offer a highly targeted route for future drug development.

Researchers have developed a novel GLP-1 receptor agonist that preserves blood sugar control while reducing nausea and vomiting, offering a potential safer approach to treating diabetes and obesity.

Scientists have identified Aurora-related kinase 1 (ARK1) as a vital protein in malaria parasite development, a breakthrough that could enable future drugs designed to block transmission.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.